<DOC>
	<DOCNO>NCT02999373</DOCNO>
	<brief_summary>About 37 % neonatal mortality cause infection worldwidely . Excessive application broad-spectrum antibiotic increase drug-resistance , however decrease morbility mortality neonate . Based investigator ' early vitro experiment find cord blood mononuclear cell inhibit bacterial growth reduce drug-resistance , along study conduct recently group report successful use umbilical cord blood mononuclear cell animal sepsis.The investigator would like investigate effect umbilical cord blood mononuclear cell prevention effect preterm infection .</brief_summary>
	<brief_title>Prevention Preterm Infection Autologous Umbilical Cord Blood Mononuclear Cells Therapy</brief_title>
	<detailed_description>This Phase 1 clinical trial constitutes two time point cohorts 80 participant per cohort receive intravenous dos Autologous Umbilical Cord Blood Mononuclear Cells -- 25 million cells/kg,6 hour 48 hour birth . And placebo 0.9 % sodium chloride.The investigator proceed group period . 1 . Eligibility Criteria : Preterm ( gestational age 28weeks less 37weeks ) 2 . Exclusion criterion : Preterm infant major congenital malformation , chromosomal anomaly , inborn error metabolism clinical laboratory evidence congenital infection 3 . Demographic Data Baseline Characteristics Studied Groups collect : Gestational age ( week ) Birth weight ( g ) gender Cesarean section delivery Antenatal steroid Prolonged rupture membrane Multiple pregnancy APGAR score 5 minute Thrombocytopenia intervention CRP intervention ( mg/L ) TNF-α ( tumor necrosis factor α ) intervention ( pg/mL ) 4 . Assessment clinical condition course measurement arterial blood pressure , heart respiratory rate skin temperature record continuously 5 . Autologous cord blood mononuclear cell dose 25 million cells/kg ，the infusion speed 4ml/kg/h， 8-12h，and volume 0.9 % sodium chloride placebo . When clinical symptom suggest infection , blood culture perform administration antibiotic , antibiotic adjust accord susceptibility isolate bacteria . 6 . The following monitor 3、7、14、21days birth : panel cytokine biomarkers ( CRP、TNF-α、IL-6、IL-10、MCP-1 ) examine Elisa , circulate stem cell level , immune cell subgroup , platelet activation relate marker CD62P、CD63 , number megakaryocyte evaluate flow cytometry , infectious rate , mortality , incidence multiple drug-resistant bacteria , clinical complication : sepsis , bronchopulmonary dysplasia ( BPD ) , retinopathy prematurity ( ROP ) , necrotising enterocolitis ( NEC ) , intraventricular haemorrhage ( IVH ) , anaemia hospital discharge 7 . Long-term follow : 1m , 3m , 6m,1y : neurodevelopment [ Bayley Scales Infant ] , asthma , anemia physique growth .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Perinatal Death</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Bacteroides Infections</mesh_term>
	<criteria>twentyeight week thirtyseven week Preterm infant major congenital malformation , chromosomal anomaly , inborn error metabolism clinical laboratory evidence congenital infection</criteria>
	<gender>All</gender>
	<minimum_age>28 Weeks</minimum_age>
	<maximum_age>36 Weeks</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>prevention , infection , preterm , cord blood mononuclear cell</keyword>
</DOC>